 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for August 23, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| KZIA | Hot Stocks20:50 EDT Kazia Therapeutics announces Orphan Drug Designation for paxalisib - Kazia Therapeutics announced that the Food and Drug Administration has granted Orphan Drug Designation to paxalisib for the treatment of malignant glioma, which includes diffuse intrinsic pontine glioma, a childhood brain cancer. Receipt of Orphan Drug Designation follows award of Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma on August 7, the company added. "This award of ODD concludes a program of regulatory optimisation that Kazia has initiated for paxalisib over the past six months. As we orient paxalisib towards commercialization, these special designations from FDA will allow us to move forward in the swiftest and most effective way possible," said Kazia CEO Dr James Garner.
|
| SPX SPY | Hot Stocks18:48 EDT FDA issues Covid-19 emergency use authorization for convalescent plasma - The Food and Drug Administration issued an emergency use authorization for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. "Based on scientific evidence available, the FDA concluded, as outlined in its decision memorandum, this product may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product," the agency said in a statement. The EUA authorizes the distribution of COVID-19 convalescent plasma in the U.S. and its administration by health care providers to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients with COVID-19. Reference Link
|
